Moderna (NASDAQ: MRNA) reported Q2 EPS of ($1.97), $0.06 better than the analyst estimate of ($2.03). Revenue for the quarter came in at $100 million versus the consensus estimate of $99.91 million.

For earnings history and earnings-related data on Moderna (MRNA) click here.